Literature DB >> 15751046

AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypes.

Torsten Haferlach1, Alexander Kohlmann, Susanne Schnittger, Martin Dugas, Wolfgang Hiddemann, Wolfgang Kern, Claudia Schoch.   

Abstract

Acute promyelocytic leukemia (APL) with t(15;17) appears in two phenotypes: AML M3, with abnormal promyelocytes showing heavy granulation and bundles of Auer rods, and AML M3 variant (M3v), with non- or hypogranular cytoplasm and a bilobed nucleus. We investigated the global gene expression profiles of 35 APL patients (19 AML M3, 16 AML M3v) by using high-density DNA-oligonucleotide microarrays. First, an unsupervised approach clearly separated APL samples from other AMLs characterized genetically as t(8;21) (n = 35), inv(16) (n = 35), or t(11q23)/MLL (n = 35) or as having a normal karyotype (n = 50). Second, we found genes with functional relevance for blood coagulation that were differentially expressed between APL and other AMLs. Furthermore, a supervised pairwise comparison between M3 and M3v revealed differential expression of genes that encode for biological functions and pathways such as granulation and maturation of hematologic cells, explaining morphologic and clinical differences. Discrimination between M3 and M3v based on gene signatures showed a median classification accuracy of 90% by use of 10-fold CV and support vector machines. Additional molecular mutations such as FLT3-LM, which were significantly more frequent in M3v than in M3 (P < 0.0001), may partly contribute to the different phenotypes. However, linear regression analysis demonstrated that genes differentially expressed between M3 and M3v did not correlate with FLT3-LM. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2005        PMID: 15751046     DOI: 10.1002/gcc.20175

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  9 in total

Review 1.  Not Only Mutations Matter: Molecular Picture of Acute Myeloid Leukemia Emerging from Transcriptome Studies.

Authors:  Luiza Handschuh
Journal:  J Oncol       Date:  2019-07-30       Impact factor: 4.375

Review 2.  Clinical implications of gene expression profiling of acute myeloid leukemia.

Authors:  Kenneth I Mills; Amanda F Gilkes
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

3.  Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group.

Authors:  Martin S Tallman; Haesook T Kim; Pau Montesinos; Frederick R Appelbaum; Javier de la Serna; John M Bennett; Guillermo Deben; Clara D Bloomfield; Jose Gonzalez; James H Feusner; Marcos Gonzalez; Robert Gallagher; Jose D Gonzalez-San Miguel; Richard A Larson; Gustavo Milone; Elisabeth Paietta; Chelo Rayon; Jacob M Rowe; Concha Rivas; Charles A Schiffer; Edo Vellenga; Lois Shepherd; James L Slack; Peter H Wiernik; Cheryl L Willman; Miguel A Sanz
Journal:  Blood       Date:  2010-09-21       Impact factor: 22.113

4.  Integrative meta-analysis of differential gene expression in acute myeloid leukemia.

Authors:  Brady G Miller; John A Stamatoyannopoulos
Journal:  PLoS One       Date:  2010-03-01       Impact factor: 3.240

5.  High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples.

Authors:  Jacqueline E Payton; Nicole R Grieselhuber; Li-Wei Chang; Mark Murakami; Gary K Geiss; Daniel C Link; Rakesh Nagarajan; Mark A Watson; Timothy J Ley
Journal:  J Clin Invest       Date:  2009-05-18       Impact factor: 14.808

Review 6.  Gene expression profiling for the diagnosis of acute leukaemia.

Authors:  T Haferlach; A Kohlmann; U Bacher; S Schnittger; C Haferlach; W Kern
Journal:  Br J Cancer       Date:  2006-12-05       Impact factor: 7.640

7.  RUNX1/ETO blocks selectin-mediated adhesion via epigenetic silencing of PSGL-1.

Authors:  K Ponnusamy; N Kohrs; A Ptasinska; S A Assi; T Herold; W Hiddemann; J Lausen; C Bonifer; R Henschler; C Wichmann
Journal:  Oncogenesis       Date:  2015-04-13       Impact factor: 7.485

8.  Applications of microarray technology to Acute Myelogenous Leukemia.

Authors:  Rashmi S Goswami; Mahadeo A Sukhai; Mariam Thomas; Patricia P Reis; Suzanne Kamel-Reid
Journal:  Cancer Inform       Date:  2008-12-22

9.  Early mortality in acute promyelocytic leukemia: Potential predictors.

Authors:  Can Chen; Xilian Huang; Kaile Wang; Kuang Chen; Danquan Gao; Shenxian Qian
Journal:  Oncol Lett       Date:  2018-01-24       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.